BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Global Biodefense - ECPv6.17.5.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://globalbiodefense.com
X-WR-CALDESC:Events for Global Biodefense
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/London
BEGIN:DAYLIGHT
TZOFFSETFROM:+0000
TZOFFSETTO:+0100
TZNAME:BST
DTSTART:20190331T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0100
TZOFFSETTO:+0000
TZNAME:GMT
DTSTART:20191027T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0000
TZOFFSETTO:+0100
TZNAME:BST
DTSTART:20200329T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0100
TZOFFSETTO:+0000
TZNAME:GMT
DTSTART:20201025T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0000
TZOFFSETTO:+0100
TZNAME:BST
DTSTART:20210328T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0100
TZOFFSETTO:+0000
TZNAME:GMT
DTSTART:20211031T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:America/Los_Angeles
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20190310T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20191103T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20200308T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20201101T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20210314T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20211107T090000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20190310T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20191103T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20200308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20201101T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20210314T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20211107T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20220313T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20221106T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20230312T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20231105T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20240310T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20241103T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Europe/London:20201001T100000
DTEND;TZID=Europe/London:20201001T110000
DTSTAMP:20200927T192759Z
CREATED:20200927T192759Z
LAST-MODIFIED:20200927T192759Z
UID:47216-1601546400-1601550000@globalbiodefense.com
SUMMARY:Accelerating Detection of Disease: UKRI Industry Briefing for Life Sciences Sector
DESCRIPTION:The UK Research and Innovation (UKRI)-funded Accelerating Detection of Disease (ADD) program will host a webinar on 1 October 2020 for life science companies to learn more about partnering and investment opportunities. \nOver the next four years the ADD program will recruit five million volunteers to support research intended to improve early detection\, risk stratification\, and early intervention for chronic diseases. \nADD volunteers will provide biological samples and health related data. With their consent\, volunteers’ data will be linked to NHS records\, and ADD will also offer volunteers feedback about their health\, if they choose. Some will be invited to provide repeat samples and join follow-on studies designed to test the potential of new diagnostic tests or treatments\, particularly if they’re at higher risk for certain diseases. \nThe unrivalled depth and detail of the ADD initiative will make it a unique resource for health research. Researchers from across academia and industry will have the chance to work with ADD to conduct studies that could improve the way we detect\, diagnose and treat diseases. \nSpeakers at the seminar include: \n\nAlison Cave\, Accelerating Detection of Disease challenge director at UK Research and Innovation\nAndrew Roddam\, CEO\, Early Disease Detection Research Project UK Ltd\, the charity that runs the ADD programme\nFiona Reddington\, Exec Director of Partnerships\, Early Disease Detection Research Project UK Ltd.\n\nADD is funded by £79 million from UKRI’s Industrial Strategy Challenge Fund which is expected to be matched by funding of up to £160 million from industry.
URL:https://globalbiodefense.com/event/accelerating-detection-of-disease-ukri-industry-briefing-for-life-sciences-sector/
CATEGORIES:Industry Day,Webinar-Webcast
LOCATION:
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201027
DTEND;VALUE=DATE:20201028
DTSTAMP:20200927T165438Z
CREATED:20200802T163328Z
LAST-MODIFIED:20200927T165438Z
UID:47192-1603756800-1603843199@globalbiodefense.com
SUMMARY:BARDA Industry Day 2020
DESCRIPTION:The Biomedical Advanced Research and Development Authority (BARDA) will host a virtual Industry Day on October 27\, 2020 to learn about U.S. Government medical countermeasure priorities\, interact with the BARDA and HHS ASPR teams\, and network with public and private sector colleagues. \nFeatured speakers and breakout presenters will address the many ways BARDA is actively addressing the current COVID-19 pandemic crisis and forging new partnerships while remaining vigilant and prepared for any new threats that may arise. \nBARDA Industry Day 2020 will include breakout sessions\, virtual networking opportunities\, and an address by Acting BARDA Director\, Dr. Gary Disbrow. Lightning Talk sessions will be available to selected applicants\, which provide an opportunity to present their technologies to an audience of BARDA specialists\, industry partners\, and potential collaborators. \nThe conference is open to anyone in the public who wishes to attend. The content is mainly geared towards healthcare research professionals and medical countermeasure developers\, government agency staff\, pharmaceutical professionals\, and scientific researchers and academics. \nThe breakout sessions and plenary discussions will be available for viewing on the conference website after the event \nLearn more: http://bit.ly/bardaindustryday2020 \nEditor’s Update 31 Aug: The Lightning Talks application submission period is now closed. Event registration is still open.
URL:https://globalbiodefense.com/event/barda-industry-day-2020/
CATEGORIES:Government Hosted,Industry Day,Webinar-Webcast
ATTACH;FMTTYPE=image/jpeg:https://globalbiodefense.com/wp-content/uploads/2020/09/barda-industry-day-2020.jpg
LOCATION:
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201214
DTEND;VALUE=DATE:20201218
DTSTAMP:20200927T230726Z
CREATED:20200927T230726Z
LAST-MODIFIED:20200927T230726Z
UID:47223-1607904000-1608249599@globalbiodefense.com
SUMMARY:Brookhaven Laboratory Workshop for Industry Researchers
DESCRIPTION:Do you have an R&D challenge that you can’t solve with traditional commercial techniques? This specialized virtual workshop will offer access to unique x-ray\, electron and optical techniques\, which are designed for understanding materials in unprecedented ways. \nBrookhaven National Laboratory will host a virtual workshop on December 14-17\, 2020 for industry researchers to showcase the capabilities and expertise available at U.S. Department of Energy (DOE) Office of Science User Facilities located at Brookhaven Lab. \nThe workshop is designed to benefit both researchers who have previously used Brookhaven facilities for their work and those who are interested in learning about accessing them for the first time. \nThe workshop will inform researchers from industry about the leading-edge capabilities and expertise at Brookhaven facilities\, and provide details about the mechanisms for accessing them. The workshop will also more broadly introduce participants to DOE programs designed to support industry research. \nThe workshop agenda will feature presentations from industry users of Brookhaven Lab facilities\, question-and-answer sessions\, and opportunities to directly hear from Department of Energy program managers for your questions. \nHighlighted presentations include: \n\nBio and pharmaceuticals\nNanofabrication; Materials synthesis and characterization\nInnovative Chemistry through Advanced Microscopy Techniques\, Ke‐Bin Low\, BASF\nBio‐inspired invisible glass: from nature to commercialization\, Calvin Cheng\, Edgehog\nOverview of capabilities of NSLS‐II and CFN\, John Hill\, BNL\nX‐ray diffraction/scattering\nElectron microscopy\nHard and soft x‐ray spectroscopy\nAdvanced UV and x‐ray probes\nImaging and microscopy\nAdvanced optical spectroscopy and microscopy\nLessons learned as industry users of BNL facilities ‐‐ panel discussion\nDOE SBIR/STTR Program\, Manny Oliver\, SBIR/STTR Program Office\, DOE\nDOE TIR Program\, Eli Levine\, Advanced Manufacturing Office\, DOE\nDOE TCF Program\, Zack Baize\, Office of Technology Transitions\, DOE\nStrategic Partnership Program\, Ivar Strand\, BNL\nHelp desk and other DOE user facilities Q&A\nHow to become an industrial user and access facilities – Jun Wang (EPS)\nHow to write a good nonproprietary industrial proposal – Lisa Miller (NSLS‐II)\, Priscilla\nAntunez (CFN)\n\nThe workshop will provide a unique “facilities open house” format\, where attendees will spend time remotely in the labs observing Brookhaven’s capabilities in action and engaging in technical discussions with Brookhaven experts. The workshop will also provide an opportunity for attendees to remotely measure their own samples\, collecting meaningful data to take home that day. \nLearn more
URL:https://globalbiodefense.com/event/brookhaven-laboratory-workshop-for-industry-researchers/
LOCATION:Brookhaven Lab – Berkner Hall\, Lewis Road\, Upton\, 11973\, United States
CATEGORIES:Government Hosted,Industry Day,Webinar-Webcast
ATTACH;FMTTYPE=image/jpeg:https://globalbiodefense.com/wp-content/uploads/2020/09/brookhaven-national-lab-doe-science-user-facilities-industry-researchers-event.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20210312T110000
DTEND;TZID=America/New_York:20210312T130000
DTSTAMP:20210301T213238Z
CREATED:20210201T205228Z
LAST-MODIFIED:20210301T213238Z
UID:48716-1615546800-1615554000@globalbiodefense.com
SUMMARY:BARDA Vaccines Against AMR Threats Virtual Workshop
DESCRIPTION:Join the Biomedical Advanced Research and Development Authority (BARDA) at the Vaccines against AMR Threats virtual workshop on March 12\, 2021 from 11:00am – 1:00pm Eastern. \nMulti-drug resistant (MDR) organisms are a threat to national security and public health. As rates of antimicrobial resistance (AMR) in pathogens continue to increase new therapeutics and vaccines are essential to combat the growing crisis. \nJoin the workshop to learn more about BARDA and how they plan to tackle this growing threat. \nHighlights from the agenda include: \n\nBARDA Introduction: Dr. Gary Disbrow\, BARDA Director\nCBRN Overview: Dr. Christopher Houchens\, CBRN Director\nAntibacterials Branch Overview: Dr. Mark Albrecht\, Antibacterials Branch Chief\nVaccines Branch Overview: Dr. Daniel Wolfe\, Vaccines Branch Chief (Acting)\nCARB-X Overview: Dr. Cameron Bess\, CARB-X Program Manager\nAMR Threats of Interest for Funding Opps: Dr. Julie Bergmann\, Dr. Lindsay Parish\, Dr. Rushyannah Killens-Cade\, CBRN Project Officers\nBARDA Solicitation Process: Ms. Jill Johnson\, DCMA Branch Chief\nQ&A Structured Discussion: Dr. Julie Bergmann\, Dr. Lindsay Parish\, Dr. Rushyannah Killens-Cade\, CBRN Project Officers\n\nVisit MedicalCountermeasures.gov for more information on this event. \n  \n 
URL:https://globalbiodefense.com/event/barda-vaccines-against-amr-threats-virtual-workshop/
CATEGORIES:Government Hosted,Industry Day,Webinar-Webcast
LOCATION:
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210420
DTEND;VALUE=DATE:20210422
DTSTAMP:20210227T184218Z
CREATED:20210227T184218Z
LAST-MODIFIED:20210227T184218Z
UID:48698-1618876800-1619049599@globalbiodefense.com
SUMMARY:APBI 2021 - APG Advanced Planning Briefing to Industry
DESCRIPTION:Team Aberdeen Proving Ground (APG) is hosting the APG Advanced Planning Briefing to Industry (APBI) on April 20-21\, 2021 via virtual format. \nThe goal of the APG APBI is to describe for industry potential future contracting opportunities for mission areas that focus on: \n\nChemical and Biological Defense\nCommand\, Control\, Communications\, Computers\, Cyber\, Intelligence\, Surveillance\, and Reconnaissance\nResearch and Development\nTest and Evaluation\nAPG Garrison\n\nThe APG APBI will be unclassified and open to all interested contractors\, large and small businesses\, and academia\, as well as other Government stakeholders. \nAdditional details will be posted at beta.SAM.gov as updates become available.
URL:https://globalbiodefense.com/event/apbi-2021-apg-advanced-planning-briefing-to-industry/
CATEGORIES:Government Hosted,Industry Day,Webinar-Webcast
LOCATION:
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210929
DTEND;VALUE=DATE:20210930
DTSTAMP:20210919T003055Z
CREATED:20210919T003055Z
LAST-MODIFIED:20210919T003055Z
UID:49670-1632873600-1632959999@globalbiodefense.com
SUMMARY:TEI-REX Proposer's Day
DESCRIPTION:The Intelligence Advanced Research Projects Activity (IARPA) will hold a virtual Proposers’ Day for the TEI-REX Program (Targeted Evaluation of Ionizing Radiation Exposure) on September 29\, 2021 from 10:00 am to 5:00 pm EDT with potential overflow into September 30\, 2021 from 10:00 am to 1:00 pm. \nThe TEI-REX Proposers’ Day meeting will be used to introduce the research requirements to potential performers and provide information on program objectives. The TEI-REX Program aims to establish novel biodosimetry approaches enabling improved quantification of low-dose ionizing radiation exposures (<0.75 Gray) from minimally and non-invasive samples\, while also expanding quantitative and qualitative knowledge of the exposure environment. \nIARPA holds Proposers’ Days to provide information to assist potential proposers to evaluate whether and how they might respond to the Government’s research and development solicitations and to increase efficiency in proposal preparation and evaluation. The TEI-REX Proposers’ Day is open only to registered potential proposers\, and not to the media or the general public. \nThe meeting will be held entirely on the WebEx video conference platform\, and a recorded video of the meeting will be made available to the public on the IARPA website. \nPre-registration is required and closes on September 24\, 2021 at 5:00 pm EDT. \nOpportunities to facilitate teaming are available to registrants for the TEI-REX Proposers’ Day. IARPA highly encourages potential proposers to establish strong teams capable of addressing the technical challenges TEI-REX aims to overcome. \nThis meeting will include an introduction to IARPA\, an overview of the program\, technical challenges\, and expected participation requirements. Before the Proposers’ Day meeting\, attendees may submit comments or questions regarding TEI-REX by emailing the program manager (contact information at the event link).
URL:https://globalbiodefense.com/event/tei-rex-proposers-day/
CATEGORIES:Government Hosted,Industry Day
LOCATION:
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20211103
DTEND;VALUE=DATE:20211105
DTSTAMP:20210812T192722Z
CREATED:20210812T192722Z
LAST-MODIFIED:20210812T192722Z
UID:49489-1635897600-1636070399@globalbiodefense.com
SUMMARY:BARDA Industry Day 2021 – BID2021
DESCRIPTION:This BARDA Industry Day 2021 Virtual Event will be held 3-4 November 2021. \nThis annual gathering of more than 1300 stakeholders from the public and private sector provides an opportunity to increase understanding of the U.S. government medical countermeasure priorities and funding goals; interact with BARDA and ASPR staff; and showcase innovations. \nInnovators may apply for limited openings to present during Lightning Talks sessions. Lightning Talks are for individuals\, academic institutions\, pharmaceutical companies\, biotech\, and other industry innovators to showcase their innovative technologies. \nTo submit your application for the Lightning Talks\, please enter the requested information and provide a brief (maximum 500 words) summary of your proposed presentation\, with one optional PowerPoint slide\, by 16 August. \nVisit the BARDA Industry Day website for more information. \n  \n 
URL:https://globalbiodefense.com/event/barda-industry-day-2021-bid2021/
CATEGORIES:Conference,Government Hosted,Industry Day
ATTACH;FMTTYPE=image/jpeg:https://globalbiodefense.com/wp-content/uploads/2021/08/bid-2021-barda-industry-day.jpg
LOCATION:
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20221206T100000
DTEND;TZID=America/New_York:20221206T170000
DTSTAMP:20220921T172133Z
CREATED:20220921T171951Z
LAST-MODIFIED:20220921T172133Z
UID:56410-1670320800-1670346000@globalbiodefense.com
SUMMARY:FDA BAA Industry Day 2022
DESCRIPTION:The U.S. Food and Drug Administration FDA will host an Industry Day on 6 December 2022 to discuss a Broad Agency Announcement (BAA) for state of the art advancements in technology\, materials\, processes\, methods\, devices\, and techniques in pharmaceutical regulatory science. \nFDA funds extramural research through an agency-wide Broad Agency Announcement (BAA) for research and development to support regulatory science and innovation. Join the event to learn more about the FY 2023 BAA\, and how to apply. \nThe FDA BAA Industry Day 2022 will be held in virtual webcast format and is open to all responsible sources. Small businesses are strongly encouraged to participate. BAA Offerors may include single entities or teams from private sector organizations\, Federally Funded Research and Development Centers (FFRDCs)\, and academic institutions. \nThe FY 2023 FDA BAA has not yet been released at the time of this event listing (21 Sep 22). The FY 2022 FDA BAA is available here for reference.
URL:https://globalbiodefense.com/event/fda-baa-industry-day-2022/
CATEGORIES:Government Hosted,Industry Day
ATTACH;FMTTYPE=image/jpeg:https://globalbiodefense.com/wp-content/uploads/2022/09/fda-baa-2022-industry-day-broad-agency-announcement.jpg
LOCATION:
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230724
DTEND;VALUE=DATE:20230729
DTSTAMP:20230421T161848Z
CREATED:20230421T161759Z
LAST-MODIFIED:20230421T161848Z
UID:56962-1690156800-1690588799@globalbiodefense.com
SUMMARY:Just Breathe: ARDS Therapeutics Pitch Event
DESCRIPTION:A BARDA-Sponsored Phase 2 ARDS Platform Clinical Trial \nBARDA will host ‘Just Breathe – An ARDS Therapeutics Pitch Event’ on July 24-28\, 2023 to support development of threat-agnostic and host-directed therapeutic candidates to address acute respiratory distress syndrome (ARDS). The event will be held in a virtual format. \nThe Biomedical Advanced Research and Development Authority Influenza & Emerging Infectious Diseases Division plans to support a randomized\, double-blinded\, placebo-controlled\, multi-center U.S. Phase 2 platform clinical trial that investigates multiple immune modulators or other host-directed therapeutics in hospitalized adult patients with acute respiratory distress syndrome (ARDS). In this trial\, BARDA will evaluate the safety and efficacy of novel threat-agnostic and host-directed therapeutics that could address ARDS caused by known or unknown health security threats such as pandemic influenza\, COVID-19\, other emerging infectious diseases\, and chemical\, biological\, radiological\, and nuclear (CBRN) incidents. \nMore information about the design of the phase 2 ARDS platform clinical trial is available in the draft protocol synopsis under the BAA Area of Interest (AOI) 9.7 (closed March 14\, 2023). \nTo participate in the Just Breathe Pitch Event\, drug sponsors will need to submit the following: \n\nSlide deck containing the required information about the proposed therapeutic candidate\nA current Investigator’s Brochure (IB) for the proposed therapeutic candidate\nSubmission cover page form\n\nInterested drug sponsors will have the opportunity to submit questions and receive feedback from BARDA on their initial slide deck submissions for revision and submit the updated slide deck for for the event. \nThe final (revised) slide deck submission and the IB will be evaluated by a scientific review process based on pre-specified criteria outlined in the presentation template. Drug sponsors with most competitive submissions will be invited to present virtually about their products and attend a live Q&A in front of an interagency review panel. \nUp to three phase 2-ready therapeutic candidates representing different mechanisms of action will be selected for inclusion in the planned BARDA-sponsored phase 2 ARDS platform clinical trial. \nPlease visit BARDA’s Influenza & Emerging Infectious Diseases Division website for additional program information and visit the Just Breathe – An ARDS Therapeutics Pitch Event page for submission instructions\, provided templates\, evaluation criteria\, and a detailed timeline. All pre-submission inquiries and submissions should be submitted to IEIDD_Tx@hhs.gov. Critical due dates for this pitch event are listed below: \n\nFinal day to submit questions: May 26\, 2023\, by 5 p.m. EDT\nInitial slide deck submission: June 2\, 2023\, by 5 p.m. EDT\nFinal (revised) slide deck submission: June 30\, 2023\, by 5 p.m. EDT\nPitch event presentation invitations to drug sponsors with the most competitive therapeutic candidates: July 10\, 2023\nJust Breathe – An ARDS Therapeutics Pitch Event: July 24-28\, 2023\n\nSource: Biomedical Advanced Research and Development Authority
URL:https://globalbiodefense.com/event/just-breathe-ards-therapeutics-pitch-event/
CATEGORIES:Government Hosted,Industry Day,Innovation Challenge
ATTACH;FMTTYPE=image/png:https://globalbiodefense.com/wp-content/uploads/2023/04/barda-just-breathe-ards-clinical-trial-therapeutics.png
LOCATION:
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20231113
DTEND;VALUE=DATE:20231115
DTSTAMP:20231017T165957Z
CREATED:20231016T173338Z
LAST-MODIFIED:20231017T165957Z
UID:59385-1699833600-1700006399@globalbiodefense.com
SUMMARY:BARDA Industry Day - BID2023
DESCRIPTION:The annual BARDA Industry Day (BID) conference will be held 13-14 November 2023 in Washington DC and via virtual participation. \nBID2023: Driving Innovation for Preparedness & Response will feature presentations from BARDA leadership\, U.S. government partners\, and industry on medical countermeasure (MCM) priorities and public health innovation. Attendees will also have an informal opportunity to interact with BARDA and ASPR teams and identify areas of potential collaboration in the field of MCM research and development. \nThe event lineup will have an assortment of BARDA program briefings\, guest speakers\, networking opportunities\, and specialized breakout sessions. Content will focus on BARDA’s efforts to collaborate across government and industry to continually innovate MCMs to address current and future health security threats. \nBARDA’s Influenza and Emerging Infectious Diseases Division (IEIDD) will give a broad ranging presentation on BARDA’s strategy for vaccine development through licensure including harmonized clinical trials\, centralized immune endpoint assays\, determination of correlates of protection\, lessons learned from the COVID-19 vaccine portfolio\, and assay-generated data for accelerated decision making. \nBARDA’s Division of Chemical\, Biological\, Radiological\, And Nuclear (CBRN) Countermeasures will provide an overview of its strategic priorities for branch and division level efforts. Among these priorities include CBRN’s plans to expand the nation’s capabilities to respond to any CBRN health security incident\, whether naturally occurring or intentional. Following the presentations\, a moderated Q&A panel will provide a deeper dive into how division-level priorities can shape medical countermeasure development going forward. \nBARDA program representatives\, industry partners\, and developers will provide an overview of animal models developed in laboratories of network performers funded through the Biological\, Chemical\, and Radiological Indefinite Delivery/Indefinite Quantity (ID/IQ) contract. In addition\, selected product developers funded by BARDA’s nonclinical network will share information on the use of animal models in efforts to license products for use against biodefense threats. \nBARDA’s Biopharmaceutical Manufacturing Preparedness (BioMaP) program has a three-pronged approach to address key vaccine manufacturing gaps to bring the nation up to the speed and scale required for future public health emergencies. In this session\, the BioMaP team will discuss these three components: the BioMaP-Consortium\, the Exercise (BioMaP-X)\, and the BioMaP Workforce Development (BioMaP-W). Join BARDA’s Pharmaceutical Countermeasures Infrastructure Division (PCI) to learn about these different aspects of the BioMaP program. \nSpeakers from the U.S. Food and Drug Administration’s (FDA) Medical Countermeasures Initiative will also address the coordination of emergency activities involving products regulated by the FDA’s Center for Drug Evaluation and Research (CDER)\, Center for Biologics Evaluation and Research (CBER)\, and Center for Devices and Radiological Health (CDRH). \nThe Division of Chemical\, Biological\, Radiological and Nuclear (CBRN)\, Division of Research\, Innovation and Ventures (DRIVe)\, and Division of Nonclinical Development (DNCD) will discuss microphysiological systems (MPS)/organ chips and how it aligns with BARDA’s portfolio. \nLearn more about BARDA Ventures – Global Health Investment Corporation (GHIC) partnership and join a discussion with GHIC on investment focus\, priorities\, and the landscape of venture investment in global health security. In addition\, learn more about the case study with Cytovale and Endpoint Health demonstrating how BARDA Ventures complements BARDA’s other investment vehicles to support MCM development and commercialization. \nA session on host-based diagnostics in sepsis will illuminate the strategic value of Host-Based Diagnostics (HBDs) in the infectious disease space and how to build a community around demonstrating the clinical utility of HBDs and streamlining their adoption and integration into practice. \nUncover BARDA’s latest initiative in clinical trial innovation pertaining to decentralized trials – the Decentralized Clinical Operations for Healthcare and Research (D-COHRe) strategic partnership. Topics include information on D-COHRe and BARDA’s fundamental interagency work towards advancing pandemic preparedness. \nPlease visit Medicalcountermeasures.gov to register. \n 
URL:https://globalbiodefense.com/event/barda-industry-day-bid2023/
LOCATION:Grand Hyatt Washington\, 1000 H St NW\, Washington DC\, 20001\, United States
CATEGORIES:Government Hosted,Industry Day
ATTACH;FMTTYPE=image/jpeg:https://globalbiodefense.com/wp-content/uploads/2023/10/barda-industry-day-2023.jpg
END:VEVENT
END:VCALENDAR